Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

101. Early Breast Cancer: ESMO Clinical Practice Guidelines

-abstract/doi/10.1093/annonc/mdz173/5499075 by guest on 25 June 201917 If invasive cancer appears in the specimen, SLNB after conservative surgery is feasible and accurate for staging the axilla. Lobular neoplasia [formerly called lobular carcinoma in situ (LCIS)], unlike DCIS, is considered a non-obligate precursor to invasive cancer. It is regarded as a risk factor for future development of invasive cancer in both breasts [relative risk (RR): 5.4–12] and does not require active treatment (...) of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24: 2206-2223. 24. Dai X, Li T, Bai Z et al. Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res 2015; 5: 2929-2943. 25. Dieci MV, Radosevic-Robin N, Fineberg S et al. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after

2019 European Society for Medical Oncology

102. Alpelisib for <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. Full Text available with Trip Pro

) with placebo plus fulvestrant in patients with HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously. Patients were enrolled into two cohorts on the basis of tumor-tissue PIK3CA mutation status. The primary end point was progression-free survival, as assessed by the investigator, in the cohort with PIK3CA-mutated cancer; progression-free survival was also analyzed in the cohort without PIK3CA-mutated cancer. Secondary end points included overall response (...) Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. PIK3CA mutations occur in approximately 40% of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. The PI3Kα-specific inhibitor alpelisib has shown antitumor activity in early studies.In a randomized, phase 3 trial, we compared alpelisib (at a dose of 300 mg per day) plus fulvestrant (at a dose of 500 mg every 28 days and once on day 15

2019 NEJM Controlled trial quality: predicted high

103. Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. Full Text available with Trip Pro

incidence ratio 46.7, 95% confidence interval 27.2 to 75.4) but lower than in cisgender women (0.3, 0.2 to 0.4). Most tumours were of ductal origin and oestrogen and progesterone receptor positive, and 8.3% were human epidermal growth factor 2 (HER2) positive. In 1229 trans men, four cases of invasive breast cancer were identified (median duration of hormone treatment 15 years, range 2-17 years). This was lower than expected compared with cisgender women (standardised incidence ratio 0.2, 95% confidence (...) Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. To investigate the incidence and characteristics of breast cancer in transgender people in the Netherlands compared with the general Dutch population.Retrospective, nationwide cohort study.Specialised tertiary gender clinic in Amsterdam, the Netherlands.2260 adult trans women (male sex assigned at birth, female gender identity) and 1229 adult trans men (female sex assigned at birth

2019 BMJ

104. Perspectives on Conversations About Costs of Cancer Care of Breast Cancer Survivors and Cancer Center Staff: A Qualitative Study. Full Text available with Trip Pro

Perspectives on Conversations About Costs of Cancer Care of Breast Cancer Survivors and Cancer Center Staff: A Qualitative Study. Despite recommendations to discuss the cost of care (CoC) with patients with cancer, little formal guidance is available on how to conduct these sensitive conversations in ways that are acceptable to both patients and providers.To explore the perspectives of patients and medical and nonmedical cancer center staff on CoC conversations.In individual interviews (...) , participants were asked to discuss the content of, timing of, and ideal person to hold CoC conversations. Interviews were transcribed verbatim. Content was analyzed to identify emerging essential elements.Division of Preventive Medicine, University of Alabama at Birmingham.42 women aged 60 to 79 years with a history of breast cancer and 20 cancer center staff (6 physicians, 4 nurses, 5 patient navigators, 3 social workers, and 2 billing specialists).Both patients and providers identified reassurance

2019 Annals of Internal Medicine

105. Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study. Full Text available with Trip Pro

receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (no prior treatment of advanced disease), 95 were Asian. Patients were randomly assigned 2:1 to receive palbociclib plus letrozole or placebo plus letrozole. The primary end point was investigator-assessed PFS. Secondary end points were overall survival, objective response, patient-reported outcomes, pharmacokinetics, and safety.Median PFS was significantly longer in Asian patients who received palbociclib plus (...) Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study. In PALOMA-2, palbociclib plus letrozole significantly improved progression-free survival (PFS) as initial treatment of estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. We assessed the benefit of palbociclib plus letrozole in Asians.Of 666 enrolled postmenopausal women with estrogen

2019 Journal of global oncology Controlled trial quality: predicted high

106. Abemaciclib (Verzenios) Women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based t

of abemaciclib in combination with a non-steroidal aromatase inhibitor (NSAI) in women with HR- positive, HER2-negative advanced breast cancer. 3, 4 This study recruited post-menopausal women with confirmed HR-positive, HER2-negative locoregional or metastatic breast cancer not suitable for surgical resection or radiotherapy with curative intent, who had measurable disease or non-measurable bone-only disease as per Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1, and had adequate organ (...) issues Breast cancer is the most common cancer in women. The expression of certain receptors, such as HR and HER-2, by breast cancer cells plays an important role in determining the therapeutic efficacy of treatments. 4 Most women with HR-positive, HER2-negative advanced breast cancer receive first line treatment with endocrine therapy, with or without a CDK 4/6 inhibitor, unless the disease is considered to be imminently life-threatening or requires early relief of symptoms due to significant

2019 Scottish Medicines Consortium

107. Abemaciclib (Verzenios) For the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with fulvestrant as initial endocrine-based therap

, with confirmed HR-positive, HER2-negative locoregional or metastatic breast cancer not suitable for surgical resection. Patients had measurable disease or non- measurable bone-only disease as per Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1, adequate organ function and an Eastern Cooperative Oncology Group (ECOG) performance status of =1. Patients were required to have disease progression while receiving neoadjuvant or adjuvant endocrine therapy, =12 months after the end of adjuvant (...) endocrine therapy, or while receiving endocrine therapy for advanced breast cancer. 2, 3 Patients were randomised 2:1 to treatment with abemaciclib 150mg oral twice daily (n=446) or matching placebo (n=223) and were stratified by metastatic site (visceral, bone only, or other) and sensitivity to endocrine therapy (primary resistance or secondary resistance). Primary resistance required disease relapse while receiving the first 2 years of (neo) adjuvant endocrine therapy or experienced progression while

2019 Scottish Medicines Consortium

108. Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy

-negative breast cancer after endocrine therapy when chemotherapy is not needed immediately, is usually exemestane, tamoxifen, or exemestane plus everolimus. NICE does not recommend fulvestrant monotherapy. Clinical trial evidence suggests that compared with fulvestrant alone, abemaciclib with fulvestrant increases the length of time before the disease progresses. However, it is uncertain whether people having abemaciclib with fulvestrant live longer, because people in the trial have not been followed (...) is an incurable condition. Patient experts explained that a diagnosis of advanced breast cancer affects both people's physical and mental health. They stated that the potential of abemaciclib plus fulvestrant to postpone or avoid the need for chemotherapy is important to patients who have previously had endocrine therapy, because chemotherapy has the potential to substantially reduce quality of life. They also highlighted the importance of people living for longer without the disease progressing, therefore

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

109. West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer (Abstract)

West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer The West German Study Group PlanB trial evaluated an anthracycline-free chemotherapy standard (six cycles of docetaxel and cyclophosphamide [TC]) in the routine treatment of human epidermal growth factor receptor 2-negative early breast cancer (EBC).Patients with pT1 to pT4c, all pN+, and pN0/high-risk EBC (...) were eligible. High-risk pN0 was defined by one or more of the following: pT greater than 2, grade 2 to 3, high urokinase-type plasminogen activator/plasminogen activator inhibitor-1, hormone receptor (HR) negativity, and less than 35 years of age. After an early amendment, all HR-positive tumors underwent recurrence score (RS) testing, with chemotherapy omission recommended in RS less than or equal to 11 pN0 to pN1 disease. Patients were randomly assigned to four cycles of epirubicin (E)90

2019 EvidenceUpdates

110. 10-year performance of four models of breast cancer risk: a validation study (Abstract)

mastectomy or ovarian cancer, at least 2 months of follow-up data, and information available about family history of breast cancer. We used this selected cohort to calculate 10-year risk scores and compare four models of breast cancer risk prediction: the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm model (BOADICEA), BRCAPRO, the Breast Cancer Risk Assessment Tool (BCRAT), and the International Breast Cancer Intervention Study model (IBIS). We compared model (...) participants (ie, BRCA-negative women), and participants younger than 50 years at recruitment. We also assessed the effect that limited data input (eg, restriction of the amount of family history and non-genetic information included) had on the models' performance.After median follow-up of 11·1 years (IQR 6·0-14·4), 619 (4%) of 15 732 women selected from the ProF-SC cohort study were prospectively diagnosed with breast cancer after recruitment, of whom 519 (84%) had histologically confirmed disease

2019 EvidenceUpdates

111. Risk-reducing medications for primary breast cancer: a network meta-analysis. (Abstract)

Risk-reducing medications for primary breast cancer: a network meta-analysis. Breast cancer is the most frequently occurring malignancy and the second cause of death for cancer in women. Cancer prevention agents (CPAs) are a promising approach to reduce the burden of breast cancer. Currently, two main types of CPAs are available: selective estrogen receptor modulators (SERMs, such as tamoxifen and raloxifene) and aromatase inhibitors (AIs, such as exemestane and anastrozole).To assess (...) Clinical Trials Registry Platform (WHO ICTRP), and ClinicalTrials.gov on 17 August 2018. We handsearched reference lists to identify additional relevant studies.We included randomized controlled trials (RCTs) that enrolled women without a personal history of breast cancer but with an above-average risk of developing a tumor. Women had to be treated with a CPA and followed up to record the occurrence of breast cancer and adverse events.Two review authors independently extracted data and conducted risk

2019 Cochrane

112. Screening for Breast Cancer in Average-Risk Women: A Guidance Statement From the American College of Physicians. Full Text available with Trip Pro

Screening for Breast Cancer in Average-Risk Women: A Guidance Statement From the American College of Physicians. The purpose of this guidance statement is to provide advice to clinicians on breast cancer screening in average-risk women based on a review of existing guidelines and the evidence they include.This guidance statement is derived from an appraisal of selected guidelines from around the world that address breast cancer screening, as well as their included evidence. All national (...) is all clinicians, and the target patient population is all asymptomatic women with average risk for breast cancer.In average-risk women aged 40 to 49 years, clinicians should discuss whether to screen for breast cancer with mammography before age 50 years. Discussion should include the potential benefits and harms and a woman's preferences. The potential harms outweigh the benefits in most women aged 40 to 49 years.In average-risk women aged 50 to 74 years, clinicians should offer screening

2019 Annals of Internal Medicine

113. Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer

. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 161 1 Recommendations Recommendations 1.1 Pertuzumab, with intravenous trastuzumab and chemotherapy, is recommended for the adjuvant treatment of human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer in adults, only if: they have lymph node-positive disease the company provides it according to the commercial arrangement. 1.2 This guidance is not intended to affect (...) in the adjuvant treatment of HER2-positive early stage breast cancer at high risk of recurrence. Clinical trial evidence measuring invasive disease-free survival suggests that 1.7% fewer people with this type of cancer have invasive disease at 4 years with adjuvant pertuzumab. Evidence from people with lymph node- positive disease (that is, disease that has spread to lymph nodes in the armpit) suggests more benefit in this population, with 3.2% fewer people having invasive disease at 4 years. However

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

114. Bevacizumab (Zirabev) - cancers of the colon, rectum, breast, lung, kidney and cervix

Bevacizumab (Zirabev) - cancers of the colon, rectum, breast, lung, kidney and cervix 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. EMA/886373/2018 EMEA/H/C/004697 Zirabev (bevacizumab) An overview of Zirabev and why (...) it is authorised in the EU What is Zirabev and what is it used for? Zirabev is a cancer medicine that is used to treat adults with the following cancers: • cancer of the colon (large bowel) or the rectum (the last section of the bowel), when it has spread to other parts of the body; • breast cancer that has spread to other parts of the body; • a lung cancer called non-small cell lung cancer when it is advanced or has spread or come back, and cannot be treated with surgery. Zirabev can be used unless the cancer

2019 European Medicines Agency - EPARs

115. Accuracy of Self-Report for Cervical and Breast Cancer Screening

Accuracy of Self-Report for Cervical and Breast Cancer Screening Management Briefs eBrief-no152 -- Accuracy of Self-Report for Cervical and Breast Cancer Screening Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs eBrief-no152 -- Accuracy of Self-Report for Cervical and Breast Cancer Screening Health Services Research & Development Management eBrief no. 152 » Issue 152 April 2019 (...) The report is a product of the VA/HSR&D Evidence Synthesis Program. Evidence Brief: Accuracy of Self-Report for Cervical and Breast Cancer Screening Guideline-based breast and cervical cancer screening are considered essential health benefits and are fundamental components of high-quality primary care services in the United States. The aim of cancer screening is to identify cancers in an early stage when treatment is more likely to be effective. Accurate measurement of cancer screening rates is vital

2019 Veterans Affairs - R&D

116. Screening for Breast Cancer in Average-Risk Women Full Text available with Trip Pro

reviews showed that women aged 39 to 49 years derived the lowest absolute benefit in terms of deaths prevented ( , ) ( ). Observational studies showed larger relative reductions in breast cancer mortality ( ). Evidence from RCTs (fair quality) and observational studies (poor quality) did not show a reduction in the incidence of advanced disease with breast cancer screening in women aged 39 to 49 years (pooled results from 4 RCTs: relative risk, 0.98 [95% CI, 0.74 to 1.37]) ( ). Screening intervals (...) carcinoma in situ and other in situ lesions ( ). Overtreatment is defined as treatment of cancer that would not have negatively affected a woman's health in her lifetime. Although reliable estimates of overtreatment are not available, nearly all women diagnosed with breast cancer (including those with ductal carcinoma in situ) receive early treatment with surgery, radiation, hormone therapy, or chemotherapy. Therefore, rates of overtreatment likely resemble estimated rates of overdiagnosis ( ). Other

2019 American College of Physicians

117. Efficacy of Internet-Based Cognitive Behavioral Therapy for Treatment-Induced Menopausal Symptoms in Breast Cancer Survivors: Results of a Randomized Controlled Trial (Abstract)

Efficacy of Internet-Based Cognitive Behavioral Therapy for Treatment-Induced Menopausal Symptoms in Breast Cancer Survivors: Results of a Randomized Controlled Trial We evaluated the effect of Internet-based cognitive behavioral therapy (iCBT), with or without therapist support, on the perceived impact of hot flushes and night sweats (HF/NS) and overall levels of menopausal symptoms (primary outcomes), sleep quality, HF/NS frequency, sexual functioning, psychological distress, and health (...) -related quality of life in breast cancer survivors with treatment-induced menopausal symptoms.We randomly assigned 254 breast cancer survivors to a therapist-guided or a self-managed iCBT group or to a waiting list control group. The 6-week iCBT program included psycho-education, behavior monitoring, and cognitive restructuring. Questionnaires were administered at baseline and at 10 weeks and 24 weeks postrandomization. We used mixed-effects models to compare the intervention groups with the control

2019 EvidenceUpdates

118. Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer. Full Text available with Trip Pro

Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer. We previously reported prolonged progression-free survival and marginally prolonged overall survival among postmenopausal patients with hormone receptor-positive metastatic breast cancer who had been randomly assigned to receive the aromatase inhibitor anastrozole plus the selective estrogen-receptor down-regulator fulvestrant, as compared with anastrozole alone, as first-line therapy. We now report final survival (...) of fulvestrant to anastrozole was associated with increased long-term survival as compared with anastrozole alone, despite substantial crossover to fulvestrant after progression during therapy with anastrozole alone. The results suggest that the benefit was particularly notable in patients without previous exposure to adjuvant endocrine therapy. (Funded by the National Cancer Institute and AstraZeneca; ClinicalTrials.gov number, NCT00075764.).Copyright © 2019 Massachusetts Medical Society.

2019 NEJM Controlled trial quality: predicted high

119. Mindfulness-based stress reduction for women diagnosed with breast cancer. (Abstract)

Mindfulness-based stress reduction for women diagnosed with breast cancer. Breast cancer is the most common cancer in women. Diagnosis and treatment may drastically affect quality of life, causing symptoms such as sleep disorders, depression and anxiety. Mindfulness-based stress reduction (MBSR) is a programme that aims to reduce stress by developing mindfulness, meaning a non-judgmental, accepting moment-by-moment awareness. MBSR seems to benefit patients with mood disorders and chronic pain (...) , and it may also benefit women with breast cancer.To assess the effects of mindfulness-based stress reduction (MBSR) in women diagnosed with breast cancer.In April 2018, we conducted a comprehensive electronic search for studies of MBSR in women with breast cancer, in the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and two trial registries (World Health Organization's International Clinical Trials Registry Platform (WHO ICTRP) and ClinicalTrials.gov). We also handsearched

2019 Cochrane

120. Understanding genetic tests for men who have a family history of breast and ovarian cancer

in a number of generations. This is called a family history of cancer.5 Why do I have a family history of cancer? There are three reasons why you might have a family history of cancer. Just by chance: Breast cancer is a common disease. This means that many people have several people in their family who have developed breast cancer. Environmental factors: Many families live in similar environments. This means they often share similar diets and lifestyles. These non- inherited factors may influence (...) and/or ovarian cancer, only about 5% will have inherited a faulty gene variation in the breast cancer protection genes BRCA1 or BRCA2. 1 Quotes from men with breast cancer: 5 “I had quite a few men say to me ‘that’s a woman’s disease’ and I had to say, “No it’s not, you could get it too”. “I was very open about having breast cancer right from the start, and that helped me deal with it”. - Cancer Australia13 Chances of developing breast cancer The graph below provides the current estimates for women and men

2019 European Society of Endocrinology